Results 201 to 210 of about 149,070 (296)

Heterogeneous TP53 mutation subtypes define prognostic classification in Mantle Cell Lymphoma [PDF]

Shuozi Liu, Ping Yang, Shaowei Zhou, Weilong Zhang, Jing Wang, Lingli Wang, Chunyuan Li, Yingtong Chen, Wenxin Qi, Hongmei Jing   +9 more
openalex   +1 more source

Clinicopathological characteristics of patients with inoperable non‐small cell lung cancer harboring circulating NRF2 pathway mutations

The Journal of Pathology, EarlyView.
Abstract Lung cancer is the leading cause of global cancer‐related morbidity and mortality, with tobacco smoking as its strongest risk factor. Nuclear factor erythroid 2‐related factor 2 (NRF2) is a redox‐regulated transcription factor frequently dysregulated in non‐small cell lung cancer (NSCLC), leading to aggressive disease and resistance to therapy.
Jouni Härkönen, Satu Tiainen, Jouni Kujala, Linnea Muhonen, Ponnuswamy Mohanasundaram, Tuomas Tikkanen, Ina Pöhner, Tommi Patinen, Simone Adinolfi, Juha P Väyrynen, Päivi Auvinen, Arto Mannermaa, Petri Pölönen, Tuomas Rauramaa, Anna‐Liisa Levonen   +14 more
wiley   +1 more source

TP53 mutation predict poor prognosis in diffuse large B-cell lymphoma: a single-center study. [PDF]

Ann Hematol
Zhang H, Zhang X, Wang J, Zhang X, Lv Y, Zhu Y, Ye X, Wei J, Yang M, Xu G, Yang C, Meng H, Xie W, Jin J, Tong H, Yu W.   +15 more
europepmc   +1 more source

TP53 NP_000537.3:p.R273H [PDF]

, 2020
openaire   +1 more source

Molecular and genomic advances in breast cancer: A comprehensive review of predictive and therapeutic innovations

Precision Medical Sciences, EarlyView.
Breast cancer subtypes, estrogen receptor‐positive (ER+), HER2‐enriched, and TNBC, are defined by genomic and epigenetic signatures. Multi‐omics profiling, immunotherapy, liquid biopsy, and AI‐driven radiogenomics enable precision medicine. Tools like Oncotype DX and PAM50 support personalized care.
Samina Malik, Arif Malik, Shahzad Ahmad, Hassan Mohsin, Shazia Iqbal   +4 more
wiley   +1 more source

Bioinformatic Identification and Preliminary Validation of TP53, TGFB1, and NFE2L2 as Potential Ferroptosis-Related Regulators in Pancreatic Adenocarcinoma. [PDF]

Pharmgenomics Pers Med
Li S, Zhang C, Lv S, Zhang Z, Xu D, Xu T.   +5 more
europepmc   +1 more source

TP53 Gene Inactivation [PDF]

, 2020
openaire   +1 more source

Treatment Response and Outcomes of Prostate Cancer Patients Carrying the Germline MMS22L F722fs Mutation

The Prostate, EarlyView.
ABSTRACT Background Methyl Methanesulfonate‐Sensitivity Protein 22‐Like (MMS22L) plays a key role in homology‐directed DNA repair, and experimental models have shown that its loss confers sensitivity to Poly (ADP‐ribose) polymerase inhibitors (PARPi).
Mayuko Kanayama, Violet A. Daniels, Marta Gielzak, Alex Brame, Misop Han, Li Jia, Jianfeng Xu, Tamara L. Lotan, Mario A. Eisenberger, Catherine H. Marshall, Patrick C. Walsh, William B. Isaacs, Jun Luo   +12 more
wiley   +1 more source

Venetoclax/FluBu2 RIC transplant followed by all-oral venetoclax/decitabine maintenance for poor-risk MDS/AML. [PDF]

Blood Adv
Garcia JS, Kim HT, Murdock HM, Bosch-Vilaseca A, Panaro KM, Lim F, Fiorilla J, Auriemma E, Brock J, Gooptu M, Ho VT, Cutler CS, Shapiro R, Kelkar AH, Abel GA, DeAngelo DJ, Stone RM, Bat-Erdene D, Ryan J, Fell G, Letai A, Ritz J, Lindsley RC, Antin JH, Soiffer RJ.   +24 more
europepmc   +1 more source

TP53 NP_000537.3:p.R282G [PDF]

, 2020
openaire   +1 more source